What are the main symptoms of menopause?

Menopause symptoms often begin with vasomotor symptoms like hot flashes and night sweats, which tend to resolve over a couple of years. Longer-term complications can include vaginal dryness, atrophy, osteopenia, osteoporosis, and brain fog.

Why is HRT potentially controversial or risky?

Historically, HRT (especially estrogen-only for women with a uterus) was linked to increased uterine cancer risk. Later, the WHI study suggested increased risks for heart disease and breast cancer with combined CEE+MPA therapy, but the speaker argues the study's population and drug choices were not representative, leading to misinterpretations.

What's the difference between conjugated equine estrogen and bio-identical hormones?

Conjugated equine estrogen, used in the WHI study, is derived from horse urine. Bio-identical hormones, like estradiol and micronized progesterone used today, are chemically identical to hormones produced by the human body and are generally preferred for HRT.

Does HRT increase the risk of breast cancer?

The WHI study suggested a small increase in breast cancer risk (25-27% relative, but only 0.1% absolute) with combined estrogen and synthetic progesterone (MPA). However, estrogen-only therapy in women without a uterus showed a potential risk reduction. Modern HRT uses bio-identical hormones and different delivery methods (like transdermal patches), which may alter these risks.

What are the risks of oral estrogen versus transdermal estrogen (patches)?

Oral estrogen can increase blood coagulability, potentially raising clot risk. Transdermal estrogen, such as patches, does not appear to have this effect and may even be associated with a decreased risk of heart disease.

Can women take testosterone therapy, and what are the considerations?

Testosterone therapy can be used for women, but with caution due to less extensive data compared to men. It's typically considered for women with significantly low testosterone levels and symptoms like poor muscle mass or low libido, aiming for physiologically normal levels with topical treatments.

Key Moments

Menstruation, Menopause, and Hormone Replacement Therapy for Women

Peter Attia MD

Science & Technology3 min read23 min video

Aug 20, 2022|2,439,037 views|48,839|6,657

Save to Pod

Key Moments

TL;DR

HRT for women, particularly concerning the WHI study, is re-evaluated. Bioidentical hormones offer benefits despite past controversies.

Key Insights

The Women's Health Initiative (WHI) study, flawed in its design and patient selection, wrongly demonized hormone replacement therapy (HRT).

Testosterone is the most abundant androgen in women, even when normalized to the same units as estrogen.

The menstrual cycle involves fluctuating estrogen and progesterone, with PMS potentially linked to progesterone reduction.

Menopause symptoms like hot flashes, vaginal dryness, and bone loss necessitate treatment, which was previously hindered by misinformation.

Bioidentical estrogen and progesterone, administered via patches and micronized forms respectively, are now preferred HRT over synthetic versions.

Absolute risk increases, not relative risk, should be the basis for discussing hormone therapy's safety, especially for breast cancer.

THE TRIUMPH AND TRAGEDY OF THE WOMEN'S HEALTH INITIATIVE

The Women's Health Initiative (WHI) study, conducted in the late 1990s and early 2000s, is characterized as a major medical "screw-up." Initially designed to test the widely held belief that hormone replacement therapy (HRT) could alleviate menopausal symptoms, the study's methodology and patient selection created significant distortions. This led to widespread fear and a drastic reduction in HRT prescriptions, despite its potential benefits for women's health.

UNDERSTANDING WOMEN'S HORMONAL CYCLES

A woman's reproductive health is governed by complex hormonal fluctuations throughout her menstrual cycle. Estrogen and progesterone levels rise and fall in distinct phases: the follicular phase, leading up to ovulation, and the luteal phase, following ovulation. Premenstrual Syndrome (PMS) symptoms are believed to be linked to the sharp decline in progesterone during the final week of the cycle, suggesting a potential role for progesterone supplementation in managing these symptoms.

MENOPAUSE AND THE NECESSITY OF HORMONAL REPLENISHMENT

Menopause, marked by the cessation of menstruation, leads to a significant drop in estrogen and progesterone. This hormonal deficiency can manifest in various symptoms, including vasomotor issues like hot flashes and night sweats, vaginal atrophy causing dryness and discomfort, and long-term consequences such as osteopenia, osteoporosis, and cognitive changes often referred to as 'brain fog.'

EVALUATING THE FLAWS OF THE WOMEN'S HEALTH INITIATIVE STUDY

The WHI study suffered from several critical design flaws. It recruited post-menopausal women significantly later than typical HRT initiation, included a disproportionately unhealthy population (smokers, obese, diabetic), and excluded symptomatic women. Furthermore, it primarily used conjugated equine estrogens and a synthetic progestin (MPA), not bioidentical hormones commonly used today, potentially leading to misleading results.

REASSESSING THE RISKS AND BENEFITS OF HRT

The WHI study's headline findings of increased breast cancer and heart disease risks were based on relative, not absolute, risk increases. The absolute increase in breast cancer was minimal (0.1%), and crucially, the estrogen-only arm (for women without a uterus) showed a trend towards reduced breast cancer. This suggests that the synthetic progestin (MPA) may have been the primary driver of negative outcomes, while bioidentical hormones, especially transdermal estrogen, show more favorable risk profiles.

THE MODERN APPROACH TO HORMONE THERAPY

Current HRT practices emphasize the use of bioidentical hormones like estradiol (via transdermal patches) and micronized progesterone. For women with a uterus, progesterone is essential to protect the endometrium. In cases where systemic progesterone is poorly tolerated, localized progesterone delivery via an IUD can be a viable alternative. While testosterone therapy for women is less studied, it may be considered for specific symptoms like low libido when testosterone levels are demonstrably low.

Mentioned in This Episode

●Supplements

●Products

●Organizations

●Studies Cited

●Concepts

Risk Comparison: HRT and Breast Cancer (WHI Study)

Data extracted from this episode

Group	Absolute Risk Increase (per 1000)	Relative Risk Increase	P-value
Estrogen + MPA vs. Placebo	0.1%	25-27%	0.05
Estrogen Only vs. Placebo (women without uterus)	N/A (risk reduction, not increase)	~24% reduction	0.06-0.07

Common Questions

The WHI was a large study in the late 90s/early 2000s that aimed to test hormone replacement therapy (HRT) in post-menopausal women. Its preliminary findings, particularly regarding increased breast cancer risk, led to a drastic reduction in HRT prescriptions, a decision the speaker argues was based on flawed methodology and interpretation.

Topics

Estrogen Therapy Health & Longevity Neuroscience & the Brain Hormone Replacement Therapy Hormone Balance Women's Health Drug Safety Medicine & Clinical Progesterone Therapy Medical Studies

Mentioned in this video

Concepts

Estrogen

A key hormone in women's health, discussed in the context of its role in the menstrual cycle, menopause symptoms, and hormone replacement therapy. The speaker differentiates between bio-identical and conjugated equine estrogen.

Luteinizing Hormone

A hormone that triggers ovulation and development of the corpus luteum after ovulation.

vaginal atrophy

A long-term complication of menopause characterized by thinning, drying, and inflammation of the vaginal walls, leading to discomfort and pain during intercourse.

Osteoporosis

A condition where bones become weak and brittle, a recognized long-term complication of menopause that increases fracture risk.

testosterone

An androgen hormone, discussed in relation to its levels in women compared to estrogen and its potential use in testosterone therapy for women, though with caution due to limited data.

Factor V Leiden

A genetic mutation that increases blood clotting risk. Mentioned in the context of discussing coagulability risks associated with oral estrogen, though topical estrogen and transdermal patches do not show this increased risk.

Progesterone

A hormone crucial in the luteal phase of the menstrual cycle and in HRT. The speaker highlights its role in opposing estrogen's effects on the endometrium and discusses potential mood impacts related to its fluctuations, as well as the difference between natural and synthetic forms.

Follicle-stimulating hormone

A hormone that stimulates the growth of ovarian follicles, playing a role in estrogen production and ovulation during the menstrual cycle.

vasomotor symptoms

Symptoms associated with menopause, primarily hot flashes and night sweats, which are often among the first indicators of menopause.

uterine cancer

Cancer of the uterus, the risk of which was found to be increased by estrogen-only therapy in women with a uterus prior to the widespread understanding of the need for progesterone to oppose estrogen.

osteopenia

A condition characterized by decreased bone density, often a precursor to osteoporosis, and is a notable long-term complication of menopause.

Factor V

A clotting protein in the blood, mutations of which (like Factor V Leiden) can increase the risk of thrombosis. Discussed in relation to HRT and blood clotting.

Studies & Research

Women's Health Initiative

A large-scale study that significantly influenced the medical field's approach to hormone replacement therapy for women, with its preliminary results leading to widespread discontinuation of HRT due to perceived risks, which the speaker argues were misinterpreted.

Organizations

Allen Brain Institute

An institute that provides data on gene and protein expression in the human brain, mentioned in the context of researching the link between progesterone and emotionality.

GYN

Gynecologist, the medical professional typically responsible for managing women's reproductive health, including HRT.

NIH

The National Institutes of Health, which initiated the Women's Health Initiative study to prospectively test the epidemiological findings suggesting benefits of hormone therapy.

Drugs & Medications

MPA

Medroxyprogesterone acetate, a synthetic form of progesterone used in the Women's Health Initiative study. The speaker suggests this synthetic component may have contributed to negative findings, particularly regarding breast cancer risk.

bioidentical progesterone

Progesterone that is chemically identical to hormones produced by the human body, contrasted with synthetic progestins like MPA.

conjugated equine estrogen

The form of estrogen used in the Women's Health Initiative study, derived from pregnant mare urine. The speaker contrasts this with bio-identical estradiol used in modern HRT.

oral contraception

Hormonal birth control pills, discussed regarding their long-term effects, with the speaker expressing limited experience and noting a trend towards IUDs for contraception.

topical testosterone

Testosterone applied to the skin, used in women when levels are very low and associated with symptoms like difficulty building muscle mass or low libido. The speaker emphasizes using it to achieve physiologically normal levels.

bio-identical estrogen

Estrogen that is chemically identical to hormones produced by the human body, contrasted with conjugated equine estrogen used in older studies.

Products

Progesterone-coated IUD

An intrauterine device that releases progesterone locally into the uterus, used for endometrial protection in women taking systemic estrogen who cannot tolerate oral progesterone.